ALLMedicine™ Metabolic Acidosis Center

Jun 26th, 2022 - Dedifferentiated liposarcoma (DDLPS) is a rare subtype of liposarcoma with a poor prognosis. This current case report describes a rectal DDLPS in a 68-year-old Chinese male that presented with lower abdominal pain and weight loss. Computed tomogra...

Jun 25th, 2022 - Many obesity and diet-related diseases have been observed in recent years. Insulin resistance (IR), a state of tissue resistance to insulin due to its impaired function, is a common coexisting condition. The most important predisposing factors are...

Jun 24th, 2022 - Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic ca...

Jun 23rd, 2022 - Sodium glucose cotransporter-2 (SGLT2) inhibitors are glucose-lowering drugs with proven efficacy in treating type 2 diabetes mellitus, and more recently, have been shown to improve heart failure outcomes in patients without diabetes. A rare compl...

Jun 22nd, 2022 - Monocarboxylate transporter 1 (MCT1) deficiency has recently been described as a rare cause of recurrent ketosis, the result of impaired ketone utilization in extrahepatic tissues. To date, only six patients with this condition have been identifie...

Dec 27th, 2012 - Small-bowel obstruction (SBO) represents as many as 16% of surgical admissions and more than 300,000 operations annually in the United States. The optimal strategies for the diagnosis and management of SBO continue to evolve secondary to advances ...

Jun 24th, 2022 - Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Pathogenic variant(s) in IBMFS genes are relevant to carcinogenesis in sporadic ca...

Jun 15th, 2022 - NEUTRALIZE is a prospective, randomized, double-blind, placebo-controlled, parallel, multicenter, Phase IIIb study to investigate the safety and efficacy of SZC in patients with hyperkalemia and low bicarbonate (metabolic acidosis ). The study wil...

Jun 15th, 2022 - Key interventions are: Assessment of UNa in spot urine samples after every bolus administration of loop diuretics with continuation of intravenous diuretics until resolution of clinical signs of fluid overload AND UNa <80 mmol/L Dosing of loop diu...

May 26th, 2022 - Frailty is very frequent among patients with chronic kidney disease (CKD) included in the waiting list for deceased donor kidney transplantation (KT), and outcomes are worsened in those frail recipients after KT. Frailty and poor fitness powerfull...

May 20th, 2022 - Diabetic ketoacidosis (DKA) is a common acute complication of type 1 diabetes mellitus (T1DM). DKA is characterized by hyperglycemia, metabolic acidosis, increased levels of ketone bodies in blood and urine. This leads to osmotic diuresis and seve...

Apr 13th, 2022 - Evidence summary Bicarbonate therapy demonstrates benefit in 2 meta-analyses Two recent meta-analyses evaluated studies of bicarbonate therapy in patients with CKD, and both found benefit. 1,2 A 2020 meta-analysis included 15 RCTs (N = 2445) of adu.

Jan 19th, 2022 - On the basis of the patient's history and clinical presentation, the likely diagnosis is ketosis-prone diabetes (KPD) type 2. KPD is widely thought of as an atypical diabetes syndrome, though some groups consider it to be a common clinical present.

Oct 8th, 2021 - Vancomycin is a widely used IV antibiotic due to its broad-spectrum of activity, bactericidal nature, and low rates of resistance; however, adverse effects (AEs), including nephrotoxicity, are commonly associated with its use. 1 The vancomycin ther.

May 12th, 2021 - An 88-year-old male veteran with a medical history of chronic obstructive pulmonary disease (COPD) on home oxygen, chronic alcohol use, squamous cell carcinoma of the lung status after left upper lobectomy, and a 5. 7 cm thoracic aortic aneurysm wa.

Apr 30th, 2021 - FDA expanded the indication for dapagliflozin (Farxiga) into chronic kidney disease (CKD). The drug, which first entered the market for type 2 diabetes in 2014, was approved to reduce the risk of kidney function decline, kidney failure, cardiovasc...